Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

PhRMA Considering Canada “Key Issues Team” In Response To Import Bills

  • News

Executive Summary

The Pharmaceutical Research & Manufacturers of America is considering establishing a new "key issues team" focusing on Canadian drug prices

You may also be interested in...



BIO To Propose Research Incentives For Diseases Of Developing World

The Biotechnology Industry Organization is working with the Brookings Institution to develop proposals for incentives for research into diseases of the developing world

BIO To Propose Research Incentives For Diseases Of Developing World

The Biotechnology Industry Organization is working with the Brookings Institution to develop proposals for incentives for research into diseases of the developing world

Blame Canada: Rx Reimportation To Be Subject Of Senate Hearing

Legislation authorizing prescription drug reimportation from Canada will be the subject of Senate Commerce Committee hearings this year

Table

View full table

Related Content

Pink Sheet
Tags:
Latest News

Don’t Believe The Lack Of Hype: US Drug Price Reform Is Biggest Ever

Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut

Some US FDA Decisions May Have Been Different If Technology Had Been Upgraded, Woodcock Says

Firms Advised To Prepare Now For New EU Patent System

See All
UsernamePublicRestriction

Register

PS039831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By